deltatrials
Completed PHASE3 INTERVENTIONAL 2-arm NCT02684006

A Study of Avelumab With Axitinib Versus Sunitinib In Advanced Renal Cell Cancer (JAVELIN Renal 101)

A PHASE 3, MULTINATIONAL, RANDOMIZED, OPEN-LABEL, PARALLEL-ARM STUDY OF AVELUMAB (MSB0010718C) IN COMBINATION WITH AXITINIB (INLYTA(REGISTERED)) VERSUS SUNITINIB (SUTENT(REGISTERED)) MONOTHERAPY IN THE FIRST-LINE TREATMENT OF PATIENTS WITH ADVANCED RENAL CELL CARCINOMA

Sponsor: Pfizer

Conditions Renal Cell Cancer
Interventions Avelumab (MSB0010718C) Axitinib (AG-013736) Sunitinib
Updated 40 times since 2017 Last updated: Jul 29, 2025 Started: Mar 23, 2016 Primary completion: Aug 31, 2023 Completion: Jun 26, 2024
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT02684006, this PHASE3 trial focuses on Renal Cell Cancer and remains completed. Sponsored by Pfizer, it has been updated 40 times since 2016, reflecting substantial change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

~Jan 2017 – ~Feb 2017 · 31 days · monthly snapshot~Feb 2017 – ~Mar 2017 · 28 days · monthly snapshot~Mar 2017 – ~Apr 2017 · 31 days · monthly snapshot~Apr 2017 – ~May 2017 · 30 days · monthly snapshot~May 2017 – ~Jun 2017 · 31 days · monthly snapshot~Jun 2017 – ~Aug 2017 · 2 months · monthly snapshot~Aug 2017 – ~Oct 2017 · 2 months · monthly snapshot~Oct 2017 – ~Nov 2017 · 31 days · monthly snapshot~Nov 2017 – ~Dec 2017 · 30 days · monthly snapshot~Dec 2017 – ~Jan 2018 · 31 days · monthly snapshot~Jan 2018 – ~Jun 2018 · 5 months · monthly snapshot~Jun 2018 – ~Aug 2018 · 2 months · monthly snapshot~Aug 2018 – ~Nov 2018 · 3 months · monthly snapshot~Nov 2018 – ~Dec 2018 · 30 days · monthly snapshot~Dec 2018 – ~Feb 2019 · 2 months · monthly snapshot~Feb 2019 – ~May 2019 · 3 months · monthly snapshot~May 2019 – ~Aug 2019 · 3 months · monthly snapshot~Aug 2019 – ~Dec 2019 · 4 months · monthly snapshot~Dec 2019 – ~Feb 2020 · 2 months · monthly snapshot~Feb 2020 – ~Mar 2020 · 29 days · monthly snapshot~Mar 2020 – ~Jul 2020 · 4 months · monthly snapshot~Jul 2020 – ~Dec 2020 · 5 months · monthly snapshot~Dec 2020 – ~Jan 2021 · 31 days · monthly snapshot~Jan 2021 – ~Apr 2021 · 3 months · monthly snapshot~Apr 2021 – ~Jun 2021 · 2 months · monthly snapshot~Jun 2021 – ~Sep 2021 · 3 months · monthly snapshot~Sep 2021 – ~Feb 2022 · 5 months · monthly snapshot~Feb 2022 – ~Jul 2022 · 5 months · monthly snapshot~Jul 2022 – ~Mar 2023 · 8 months · monthly snapshot~Mar 2023 – ~Aug 2023 · 5 months · monthly snapshot~Aug 2023 – ~Oct 2023 · 2 months · monthly snapshot~Oct 2023 – ~Dec 2023 · 2 months · monthly snapshot~Dec 2023 – ~Jan 2024 · 31 days · monthly snapshot~Jan 2024 – ~Jul 2024 · 6 months · monthly snapshot~Jul 2024 – ~Aug 2024 · 31 days · monthly snapshot~Aug 2024 – ~Sep 2024 · 31 days · monthly snapshot~Sep 2024 – ~Nov 2024 · 2 months · monthly snapshot~Nov 2024 – ~Aug 2025 · 9 months · monthly snapshot~Aug 2025 – ~Sep 2025 · 31 days · monthly snapshot~Sep 2025 – present · 12 months · monthly snapshot

Change History

40 versions recorded

  1. Sep 2025 — Present [monthly]

    Completed PHASE3

  2. Aug 2025 — Sep 2025 [monthly]

    Completed PHASE3

  3. Nov 2024 — Aug 2025 [monthly]

    Completed PHASE3

  4. Sep 2024 — Nov 2024 [monthly]

    Completed PHASE3

  5. Aug 2024 — Sep 2024 [monthly]

    Completed PHASE3

    Status: Active Not Recruiting → Completed

▶ Show 35 earlier versions

  1. Jul 2024 — Aug 2024 [monthly]

    Active Not Recruiting PHASE3

  2. Jan 2024 — Jul 2024 [monthly]

    Active Not Recruiting PHASE3

  3. Dec 2023 — Jan 2024 [monthly]

    Active Not Recruiting PHASE3

  4. Oct 2023 — Dec 2023 [monthly]

    Active Not Recruiting PHASE3

  5. Aug 2023 — Oct 2023 [monthly]

    Active Not Recruiting PHASE3

  6. Mar 2023 — Aug 2023 [monthly]

    Active Not Recruiting PHASE3

  7. Jul 2022 — Mar 2023 [monthly]

    Active Not Recruiting PHASE3

  8. Feb 2022 — Jul 2022 [monthly]

    Active Not Recruiting PHASE3

  9. Sep 2021 — Feb 2022 [monthly]

    Active Not Recruiting PHASE3

  10. Jun 2021 — Sep 2021 [monthly]

    Active Not Recruiting PHASE3

  11. Apr 2021 — Jun 2021 [monthly]

    Active Not Recruiting PHASE3

  12. Jan 2021 — Apr 2021 [monthly]

    Active Not Recruiting PHASE3

  13. Dec 2020 — Jan 2021 [monthly]

    Active Not Recruiting PHASE3

  14. Jul 2020 — Dec 2020 [monthly]

    Active Not Recruiting PHASE3

  15. Mar 2020 — Jul 2020 [monthly]

    Active Not Recruiting PHASE3

  16. Feb 2020 — Mar 2020 [monthly]

    Active Not Recruiting PHASE3

  17. Dec 2019 — Feb 2020 [monthly]

    Active Not Recruiting PHASE3

  18. Aug 2019 — Dec 2019 [monthly]

    Active Not Recruiting PHASE3

  19. May 2019 — Aug 2019 [monthly]

    Active Not Recruiting PHASE3

  20. Feb 2019 — May 2019 [monthly]

    Active Not Recruiting PHASE3

  21. Dec 2018 — Feb 2019 [monthly]

    Active Not Recruiting PHASE3

  22. Nov 2018 — Dec 2018 [monthly]

    Active Not Recruiting PHASE3

  23. Aug 2018 — Nov 2018 [monthly]

    Active Not Recruiting PHASE3

    Status: Recruiting → Active Not Recruiting

  24. Jun 2018 — Aug 2018 [monthly]

    Recruiting PHASE3

  25. Jan 2018 — Jun 2018 [monthly]

    Recruiting PHASE3

  26. Dec 2017 — Jan 2018 [monthly]

    Recruiting PHASE3

  27. Nov 2017 — Dec 2017 [monthly]

    Recruiting PHASE3

  28. Oct 2017 — Nov 2017 [monthly]

    Recruiting PHASE3

  29. Aug 2017 — Oct 2017 [monthly]

    Recruiting PHASE3

  30. Jun 2017 — Aug 2017 [monthly]

    Recruiting PHASE3

  31. May 2017 — Jun 2017 [monthly]

    Recruiting PHASE3

  32. Apr 2017 — May 2017 [monthly]

    Recruiting PHASE3

  33. Mar 2017 — Apr 2017 [monthly]

    Recruiting PHASE3

  34. Feb 2017 — Mar 2017 [monthly]

    Recruiting PHASE3

  35. Jan 2017 — Feb 2017 [monthly]

    Recruiting PHASE3

    First recorded

Mar 2016

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Pfizer
Data source: Pfizer

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Akita, Japan , Albany, United States , Allentown, United States , Amsterdam, Netherlands , Atlanta, United States , Auckland, New Zealand , Aurora, United States , Aviano, Italy , Ballarat, Australia , Baltimore, United States and 140 more locations